Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | THRB | P10828 | 1/20 | 0.73 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7407419 | 1.00 | MAPT (1.00) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL7404132 | 1.00 | MAPT (1.00) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL7408250 | 1.00 | MAPT (1.00) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL7408049 | 1.00 | MAPT (1.00) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL19799191 | 1.00 | MAPT (1.00) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL7415134 | 1.00 | MAPT (1.00) | MAPTTDP1LMNAPGRCYP3A4 | |
| Idebenone SCHEMBL10515979 | 1.00 | MAPT (1.00) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL7416961 | 1.00 | MAPT (1.00) | MAPTTDP1LMNAPGRCYP3A4 | |
| SCHEMBL7416239 | 1.00 | MAPT (1.00) | MAPTTDP1LMNAPGRCYP3A4 | |
| Idebenone SCHEMBL28320 | 1.00 | MAPT (1.00) | MAPTTDP1LMNAPGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246195-A1 | MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS | ANTIPODEAN PHARMACEUTICALS INC (NZ) | 2017-08-31 | — | — | US | disclosed |
| EP-1664069-B1 | MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS | ANTIPODEAN PHARMACEUTICALS INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20110288055-A1 | MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS | TAYLOR KENNETH MARTIN (NZ) | 2011-11-24 | — | — | US | disclosed |
| US-7888334-B2 | lipophilic cationic moiety linked by to an antioxidant; a salt forming anion; does not exhibit reactivity against the lipophilic cationic moiety; Parkinson's, Alzheimer's disease, Huntington's Chorea and Friedreich's Ataxia | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888335-B2 | Antioxidant: methoxyphenyl alkyl triphenylphosphonium or methoxy dioxocyclohexadiene alkyl triphenylphosphonium derivatives; Parkinson's, Alzheimer's disease, Huntington's Chorea and Friedreich's Ataxia | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| CN-1839142-B | Mitoquinone derivatives used as mitochondrially targeted antioxidants | ANTIPODEAN PHARMACEUTICALS INC | 2010-06-16 | — | — | CN | disclosed |
| US-20080161267-A1 | Mitoquinone Derivatives Used as Mitochondrially Targeted Antioxidants | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070238709-A1 | Mitoquinone Derivatives Used as Mitochondrially Targeted Antioxidants | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| US-20060229278-A1 | Mitoquinone derivatives used as mitochondrially targeted antioxidants | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| CN-1839142-A | Mitoquinone derivatives used as mitochondrially targeted antioxidants | ANTIPODEAN BIOTECHNOLOGY LTD (US) | 2006-09-27 | — | — | CN | disclosed |
| EP-1664069-A1 | MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS | Antipodean Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005019232-A1 | MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019233-A1 | MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS | ANTIPODEAN PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229278-A1 | Mitoquinone derivatives used as mitochondrially targeted antioxidants | COQ8A, MFN2, SQOR | MAPT 855/4885TDP1 1586/4885LMNA 1036/4885 |
| US-20080161267-A1 | Mitoquinone Derivatives Used as Mitochondrially Targeted Antioxidants | PRDX5, MT-ND2, TXN2 | MAPT 1444/4885TDP1 1033/4885LMNA 1538/4885 |
| US-20070238709-A1 | Mitoquinone Derivatives Used as Mitochondrially Targeted Antioxidants | PRDX5, TXNRD2, TXN2 | MAPT 1912/4885TDP1 913/4885LMNA 1329/4885 |
| US-20170246195-A1 | MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS | PRDX5, TXN2, MT-ND2 | MAPT 1463/4885TDP1 991/4885LMNA 1460/4885 |
| US-20110288055-A1 | MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS | PRDX5, MT-ND2, TXN2 | MAPT 1444/4885TDP1 1033/4885LMNA 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.